Neurofibromatosis Type 2 Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 (Albany, US) DelveInsight has launched a new report on "Neurofibromatosis 2 Market Insights, Epidemiology, and Market Forecast-2030".

DelveInsight's " Neurofibromatosis 2 Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Neurofibromatosis 2 , historical and forecasted epidemiology as well as the Neurofibromatosis 2 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of Neurofibromatosis type 2 Facts:

·         As per National Organization for Rare Disorders, the estimated incidence of NF2 is 1 in 33,000 people worldwide. The average age of onset is 18 to 24 years. [2018]

·         As per the Orphanet, the prevalence of Neurofibromatosis type 2 (initially estimated at 1: 200,000) is around 1 in 60,000. [2018]

·         According to Children’s Tumor Foundation, most people develop symptoms in the late teen and early adult years, although about 10% of people develop symptoms during late childhood.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-market

View Report: https://www.delveinsight.com/report-store/neurofibromatosis-2-market

Scope of the Report

• The report covers the descriptive overview of Neurofibromatosis 2 , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Neurofibromatosis 2 epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Neurofibromatosis 2 are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Neurofibromatosis 2 market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neurofibromatosis 2 market

Request for Free Sample Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-market

View Report: https://www.delveinsight.com/report-store/neurofibromatosis-2-market

Neurofibromatosis type 2 (NF2) is a rare genetic disorder characterized by the growth of non- cancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition.

Mutations in the NF2 gene cause neurofibromatosis type 2. The NF2 gene provides instructions for making a protein called merlin (also known as schwannomin). Merlin surrounds and insulate nerve cells (neurons) in the brain and spinal cord. Mutations in the NF2 gene lead to the production of a nonfunctional version of the merlin protein that cannot regulate the growth and division of cells.

The signs and symptoms of neurofibromatosis type 2 usually appear during adolescence or in a person's early twenties, although they can begin at any age. The most frequent early symptoms of vestibular schwannomas are hearing loss, ringing in the ears (tinnitus), and problems with balance. Complications of tumor growth can include changes in vision, numbness or weakness in the arms or legs, and fluid buildup in the brain.

Some people with neurofibromatosis type 2 also develop clouding of the lens (cataracts) in one or both eyes, often beginning in childhood.

NF2 affects males and females equally.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-market

Some of Neurofibromatosis type 2 Companies:

·         Betta Pharmaceuticals

·         AstraZeneca

·         Genentech

·         And Many Others

Neurofibromatosis type 2 Drugs Covered:

·         Icotinib

·         Selumetinib

·         Bevacizumab

·         And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-market

View Report: https://www.delveinsight.com/report-store/neurofibromatosis-2-market

Table of Contents:

1. Key Insights

2. Executive Summary of Neurofibromatosis 2

3. Competitive Intelligence Analysis for Neurofibromatosis 2

4. Neurofibromatosis 2 : Market Overview at a Glance

5. Neurofibromatosis 2 : Disease Background and Overview

6. Patient Journey

7. Neurofibromatosis 2 Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Neurofibromatosis 2 Treatment

11. Marketed Products

12. Emerging Therapies

13. Neurofibromatosis 2 : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neurofibromatosis 2

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

DelveInsght’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.   

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/